The DOI matches its Crossref record; 133 of the 134 references it cites were found in a registry or an index.
Chylomicronaemia–current diagnosis and future therapies
Abstract
This Review discusses new developments in understanding the basis of chylomicronaemia--a challenging metabolic disorder for which there is an unmet clinical need. Chylomicronaemia presents in two distinct primary forms. The first form is very rare monogenic early-onset chylomicronaemia, which presents in childhood or adolescence and is often caused by homozygous mutations in the gene encoding lipoprotein lipase (LPL), its cofactors apolipoprotein C-II or apolipoprotein A-V, the LPL chaperone lipase maturation factor 1 or glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1. The second form, polygenic late-onset chylomicronaemia, which is caused by an accumulation of several genetic variants, can be exacerbated by secondary factors, such as poor diet, obesity, alcohol intake and uncontrolled type 1 or type 2 diabetes mellitus, and is more common than early-onset chylomicronaemia. Both forms of chylomicronaemia are associated with an increased risk of life-threatening pancreatitis; the polygenic form might also be associated with an increased risk of cardiovascular disease. Treatment of chylomicronaemia focuses on restriction of dietary fat and control of secondary factors, as available pharmacological therapies are only minimally effective. Emerging therapies that might prove more effective than existing agents include LPL gene therapy, inhibition of microsomal triglyceride transfer protein and diacylglycerol O-acyltransferase 1, and interference with the production and secretion of apoC-III and angiopoietin-like protein 3.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“complete apo C-II deficiency accounts for ∼2% of all FCS cases.93”
From Clinical review on triglycerides (2020) · cites this paper as [93]
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [6]
In the citing paper
“Effectiveness of omega-3 fatty acids, routinely used in pharmacologic doses for treatment of severe HTG, has been inconsistent in patients with FCS.3,[16][17][18]20”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
In the citing paper
“Even when patients adhere to the very-low-fat diet and are monitored by a registered dietitian nutritionist (RDN), TG levels may remain dangerously high.3,20,21”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
In the citing paper
“Of note, prescription omega-3 fatty acids (up to 4 grams per day) have shown inconsistent effectiveness as a treatment for HTG in patients with FCS.3,[16][17][18][19]”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Acute pancreatitis: value of CT in establishing prognosis.
Balthazar, E. J., Robinson, D. L., Megibow, A. J., & Ranson, J. H. C. (1990) · Radiology · doi:10.1148/radiology.174.2.2296641 · Cited by 1,682
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Whitcomb, D. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054958 · Cited by 747
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationHypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
Self-citationPrakash, T. P., Graham, M., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 588
Fredrickson, D. S., & Lees, R. S. (1965) · Circulation · doi:10.1161/01.cir.31.3.321 · Cited by 507
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462
Self-citationKamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
Self-citation(1995) · PubMed · Cited by 423
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Etiological and prognostic factors in human acute pancreatitis: a review.
Ranson, J. H. C. (1982) · PubMed · Cited by 391
Mechanisms for the Hypotriglyceridemic Effect of Marine Omega-3 Fatty Acids
Davidson, M. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.024 · Cited by 383
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
Park, Y., & Harris, W. S. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200282-jlr200 · Cited by 348
van der Vliet, H. N., Groenink, M., Leegwater, A. C. J., Levels, J. H. M., Reitsma, P. H., BOERS, W., & Chamuleau, R. A. F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106888200 · Cited by 344
Benlian, P., Gennes, J. L. D., Foubert, L., Zhang, H., Gagné, S., & Hayden, M. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351203 · Cited by 296
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Genetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 264
Self-citationGoldberg, A. C., Alagona, P., Capuzzi, D. M., Guyton, J. R., Morgan, J. M., Rodgers, J. B., Sachson, R. A., & Samuel, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00703-7 · Cited by 233
Triglycerides and Heart Disease
Goldberg, I. J., Eckel, R. H., & McPherson, R. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.226100 · Cited by 224
Regulation of triglyceride metabolism by Angiopoietin-like proteins
Mattijssen, F., & Kersten, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.010 · Cited by 180
Gene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178
Molecular pathobiology of the human lipoprotein lipase gene
Murthy, V., Julien, P., & Gagné, C. (1996) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(96)00005-8 · Cited by 178
Sandhu, S., Al-Sarraf, A., Taraboanta, C., Frohlich, J., & Francis, G. A. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-157 · Cited by 167
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165
Chylomicronemia With a Mutant GPIHBP1 (Q115P) That Cannot Bind Lipoprotein Lipase
Beigneux, A. P., Franssen, R., Bensadoun, A., Gin, P., Melford, K., Peter, J., Walzem, R. L., Weinstein, M. M., Davies, B. S. J., Kuivenhoven, J. A., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.186577 · Cited by 160
Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis
Chen, J.-H., Yeh, J., Lai, H., & Liao, C. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i15.2272 · Cited by 160
Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S. L., Suri, V., Qadri, A., Gareski, T., Jones, J. E., Hahm, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.245456 · Cited by 159
Chylomicronemia Syndrome: Interaction of Genetic and Acquired Hypertriglyceridemia
Brunzell, J. D., & Bierman, E. L. (1982) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31430-4 · Cited by 154
Berberich, A. J., & Hegele, R. A. (2013) · Nutrients · doi:10.3390/nu5030981 · Cited by 143
Self-citationDomínguez‐Muñoz, J. E., Malfertheiner, P., DITSCHUNEIT, H. H., Blanco-Chavez, J., Uhl, W. H., Büchler, M. W., & DITSCHUNEIT, H. H. (1991) · PubMed · Cited by 132
Genetic bases of hypertriglyceridemic phenotypes
Johansen, C. T., & Hegele, R. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283471972 · Cited by 127
Self-citationLipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias
Johansen, C. T., Dubé, J. B., Loyzer, M. N., MacDonald, A., Carter, D. E., McIntyre, A. D., Cao, H., Wang, J., Robinson, J. F., & Hegele, R. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.d045963 · Cited by 125
Self-citationApolipoprotein A-V; a potent triglyceride reducer
Nilsson, S. K., Heeren, J., Olivecrona, G., & Merkel, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.019 · Cited by 122
N‐3 Fatty Acids from Fish Oil: Effects on Plasma Lipoproteins and Hypertriglyceridemic Patients a
CONNOR, W. E., DeFRANCESCO, C. A., & CONNOR, S. L. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35689.x · Cited by 119
Severe Hypertriglyceridemia With Pancreatitis
Sacks, F. M., Stanesa, M., & Hegele, R. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13309 · Cited by 119
Self-citationMutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia.
Olivecrona, G., Ehrenborg, E., Semb, H., Makoveichuk, E., Lindberg, A., Hayden, M. R., Gin, P., Davies, B. S. J., Weinstein, M. M., Fong, L. G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002717 · Cited by 118
GPIHBP1, an endothelial cell transporter for lipoprotein lipase
Young, S. G., Davies, B. S. J., Voss, C. V., Gin, P., Weinstein, M. M., Tontonoz, P., Reue, K., Bensadoun, A., Fong, L. G., & Beigneux, A. P. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r018689 · Cited by 117
Liver as a target for oligonucleotide therapeutics
Sehgal, A., Vaishnaw, A. K., & Fitzgerald, K. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.045 · Cited by 116
Hyperlipidemia in acute pancreatitis
Domínguez‐Muñoz, J. E., Malfertheiner, P., DITSCHUNEIT, H. H., Blanco-Chavez, J., Uhl, W. H., Buckler, M. W., & DITSCHUNEIT, H. H. (1991) · International Journal of Pancreatology · doi:10.1007/bf02924164 · Cited by 116
Prevention of Recurrent Acute Pancreatitis in Patients with Severe Hypertriglyceridemia
Piolot, A., Nadler, F., Cavallero, E., Coquard, J.-L., & JACOTOT, B. (1996) · Pancreas · doi:10.1097/00006676-199607000-00013 · Cited by 114
Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis
Ewald, N., & Kloer, H.-U. (2012) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-012-0042-x · Cited by 114
Postprandial lipemia as a cardiometabolic risk factor
Pirillo, A., Norata, G. D., & Catapano, A. L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909394 · Cited by 108
Basel‐Vanagaite, L., Zevit, N., Har‐Zahav, A., Guo, L., Parathath, S., Pasmanik‐Chor, M., McIntyre, A. D., Wang, J., Albin‐Kaplanski, A., Hartman, C., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.028 · Cited by 106
Self-citationAPOA5 and triglyceride metabolism, lesson from human APOA5 deficiency
Calandra, S., Oliva, C. P., Tarugi, P., & Bertolini, S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217892.00618.54 · Cited by 105
Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12221 · Cited by 104
DeVita, R. J., & Pinto, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007033 · Cited by 102
Diagnosis and Management of Type I and Type V Hyperlipoproteinemia
Gotoda, T., Shirai, K., Ohta, T., Kobayashi, J., Yokoyama, S., Oikawa, S., Bujo, H., Ishibashi, S., Arai, H., Yamashita, S., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10702 · Cited by 99
Arruda, V. R., Siqueira, L. H., Gon�alves, M. S., von Zuben, P. M., Soares, M. C. P., de Menezes, R. C., Annichino‐Bizzacchi, J. M., & Costa, F. F. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980724)78:4 · Cited by 99
Johansen, C. T., Wang, J., Lanktree, M. B., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., Schwartz, S. M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226365 · Cited by 97
Self-citationJohansen, C. T., Wang, J., McIntyre, A. D., Martins, R. A., Ban, M. R., Lanktree, M. B., Huff, M. W., Péterfy, M., Mehrabian, M., Lusis, A. J., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960864 · Cited by 93
Self-citationFamilial lipoprotein lipase deficiency in infancy: Clinical, biochemical, and molecular study
Feoli‐Fonseca, J. C., Levy, E. H., Godard, M., & Lambert, M. A. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70280-x · Cited by 93
Chylomicronemia and the Chylomicronemia Syndrome: A Practical Approach to Management
Leaf, D. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.10.004 · Cited by 91
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia
Skulas-Ray, A. C., West, S. G., Davidson, M. H., & Kris-Etherton, P. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1237 · Cited by 91
Lipase maturation factor 1: A lipase chaperone involved in lipid metabolism
Péterfy, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.006 · Cited by 90
Deletion of GPIHBP1 causing severe chylomicronemia
Rios, J. J., Shastry, S., Jasso, J. H. T., Hauser, N., Garg, A., Bensadoun, A., Cohen, J. C., & Hobbs, H. H. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9406-5 · Cited by 89
Wang, J., & Hegele, R. A. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-23 · Cited by 89
Self-citationGPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons
Young, S. G., Davies, B. S. J., Fong, L. G., Gin, P., Weinstein, M. M., Bensadoun, A., & Beigneux, A. P. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3281527914 · Cited by 87
Rahalkar, A. R., Giffen, F., Har, B., Ho, J., Morrison, K. M., Hill, J. S., Wang, J., Hegele, R. A., & JOY, T. R. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-005 · Cited by 86
Self-citationLennertz, A., Parhofer, K. G., Samtleben, W., & Bosch, T. P. (1999) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.1999.00158.x · Cited by 85
Hyperlipidemia in acute pancreatitis
Domínguez‐Muñoz, J. E., Jünemann, F., & Malfertheiner, P. (1995) · International Journal of Pancreatology · doi:10.1007/bf02785883 · Cited by 83
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Tremblay, A. J., Lamarche, B., Hogue, J., & Couture, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p800061-jlr200 · Cited by 81
Christian, J. B., Arondekar, B. V., Buysman, E. K., JOHNSON, S. L., Seeger, J. D., & Jacobson, T. A. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.08.007 · Cited by 78
Rouis, M., Dugi, K. A., Previato, L., Patterson, A. P., Brunzell, J. D., Brewer, H. B., & Santamarina-Fojo, S. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.7.1400 · Cited by 78
Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum
Rahalkar, A. R., & Hegele, R. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.10.007 · Cited by 77
Self-citationTherapeutic apheresis for severe hypertriglyceridemia in pregnancy
Başar, R., Üzüm, A. K., Canbaz, B., Doğanşen, S. Ç., Beşışık, S. K., Altay-Dadin, S., Aral, F., & Özbey, N. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2786-z · Cited by 72
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
Self-citationDenison, H., Nilsson, C. A. M., Kujacic, M., Löfgren, L., Karlsson, C., Knutsson, M., & Eriksson, J. W. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12002 · Cited by 69
Severe Hypertriglyceridemia: An indication for apheresis?
Ewald, N., & Kloer, H.-U. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)71810-0 · Cited by 69
Triglyceride and cholesterol metabolism in primary hypertriglyceridemia.
Beil, U., Grundy, S. M., Crouse, J. R., & Zech, L. A. (1982) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.2.1.44 · Cited by 67
New lipid-lowering drugs: an update
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02867.x · Cited by 65
Plasmapheresis as an Adjuvant Therapy for Hypertriglyceridemia-Induced Pancreatitis
Iskandar, S. B., & Olive, K. E. (2004) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200411000-00010 · Cited by 64
Beigneux, A. P., Davies, B. S. J., Bensadoun, A., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800030-jlr200 · Cited by 61
Genotype-phenotype relationships in patients with type I hyperlipoproteinemia
Chokshi, N., Blumenschein, S. D., Ahmad, Z., & Garg, A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.006 · Cited by 61
Hypertriglyceridemia: phenomics and genomics
Hegele, R. A., & Pollex, R. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0005-1 · Cited by 60
Self-citationAllelic and phenotypic spectrum of plasma triglycerides
Johansen, C. T., & Hegele, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.007 · Cited by 59
Self-citationMutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1
Voss, C. V., Davies, B. S. J., Tat, S., Gin, P., Fong, L. G., Pelletier, C., Mottler, C. D., Bensadoun, A., Beigneux, A. P., & Young, S. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100992108 · Cited by 58
Syed, H., Bilušić, M., Rhondla, C., & Tavaria, A. (2010) · Journal of Clinical Apheresis · doi:10.1002/jca.20232 · Cited by 53
Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., & Stalenhoef, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.002 · Cited by 50
Plengpanich, W., Young, S. G., Khovidhunkit, W., Bensadoun, A., Karnman, H., Ploug, M., Gårdsvoll, H., Leung, C. S., Adeyo, O., Larsson, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558528 · Cited by 48
Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
Wierzbicki, A. S., & Viljoen, A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.738663 · Cited by 48
Kitabata, H., Waksman, R., & Warnack, B. (2014) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2014.01.011 · Cited by 45
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Chan, D. C., Watts, G. F., Barrett, P. H. R., Martins, I. J., James, A. P., Mamo, J. C. L., Mori, T. A., & Redgrave, T. G. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30112-7 · Cited by 44
Naik, R., Brice, O.-O., Kim, M., Choi, Y., Lee, H. S., & Lee, K. (2014) · ChemMedChem · doi:10.1002/cmdc.201402069 · Cited by 44
Management of Hypertriglyceridemia in the Diabetic Patient
Jialal, I., Amess, W., & Kaur, M. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0124-4 · Cited by 44
The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study
Leaf, D. A. (1989) · JAMA · doi:10.1001/jama.262.22.3154 · Cited by 44
Ma, Y., Wilson, B. I., Bijvoet, S. M., Henderson, H., Cramb, E., Roederer, G. O., Murthy, M. R. V., Julien, P., Bakker, H. D., Kastelein, J. J. P., et al. (1992) · Genomics · doi:10.1016/0888-7543(92)90136-g · Cited by 43
The Complex Genetic Basis of Plasma Triglycerides
Johansen, C. T., & Hegele, R. A. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0243-2 · Cited by 42
Self-citationFamilial Chylomicronemia Syndrome
Sugandhan, S., Khandpur, S., & Sharma, V. (2007) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2007.00415.x · Cited by 42
Schober, G., Arnold, M., Birtles, S., Buckett, L. K., Pacheco‐López, G., Turnbull, A. V., Langhans, W., & Mansouri, A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m035154 · Cited by 41
Extreme hypertriglyceridemia managed with insulin
Thuzar, M., Shenoy, V. V., Malabu, U. H., Schrale, R. G., & Sangla, K. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.004 · Cited by 41
The Hypolipidemic Effects of Gemfibrozil in Type V Hyperlipidemia
LEAF, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430220077034 · Cited by 40
Martín-Campos, J. M., Julve, J., Roig, R., Martínez, S., Errico, T. L., Martínez-Couselo, S., Escolá‐Gil, J. C., Méndez‐González, J., & Blanco‐Vaca, F. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.11.025 · Cited by 39
Jap, T., Jenq, S.-F., Wu, Y.-C., Chiu, C. T., & Cheng, H.-M. (2003) · Pancreas · doi:10.1097/00006676-200308000-00003 · Cited by 38
The Pathophysiology of Pancreatitis
Khokhar, A. S., & Seidner, D. L. (2004) · Nutrition in Clinical Practice · doi:10.1177/011542650401900105 · Cited by 36
Treatment of primary chylomicronemia due to familial hypertriglyceridemia by ω-3 fatty acids
Richter, W. O., Jacob, B. G., Ritter, M. M., & SCHWANDT, P. (1992) · Metabolism · doi:10.1016/0026-0495(92)90293-j · Cited by 36
Stefanutti, C., Gozzer, M., Pisciotta, L., D’Eufemia, P., Bosco, G., Morozzi, C., Papadia, F., Shafii, M., Giacomo, S. D., & Bertolini, S. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.020 · Cited by 32
Vuorio, A. F., Tikkanen, M. J., & Kovanen, P. T. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s36641 · Cited by 32
Meyers, C. D., Gaudet, D., Tremblay, K., Amer, A., Chen, J., & Aimin, F. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.034 · Cited by 32
Albers, K., Schlein, C., Wenner, K., Lohse, P., Bartelt, A., Heeren, J., Santer, R., & Merkel, M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.009 · Cited by 30
Clark, K., James, A. P., & Mamo, J. C. L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-9 · Cited by 30
Lam, C., Yuen, Y., Cheng, W.-F., Chan, Y.-W., & Tong, S.-F. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.07.025 · Cited by 29
Lomitapide for the Management of Homozygous Familial Hypercholesterolemia
deGoma, E. M. (2014) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0735 · Cited by 27
Pschierer, V., Richter, W. O., & Schwandt, P. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1490 · Cited by 26
Gin, P., Goulbourne, C. N., Adeyo, O., Beigneux, A. P., Davies, B. S. J., Tat, S., Voss, C. V., Bensadoun, A., Fong, L. G., & Young, S. G. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds127 · Cited by 26
Familial chylomicronemia syndrome.
Mohandas, M. K., Jemila, J., Krishnan, A. S. A., & George, T. T. (2005) · PubMed · Cited by 25
Medical resource use and costs associated with chylomicronemia
Gaudet, D., Signorovitch, J., Swallow, E., Fan, L., Tremblay, K., Brisson, D., Meyers, C. D., & Gruenberger, J.-B. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.779277 · Cited by 25
Furtado, J. D., Wedel, M. K., & Sacks, F. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p021717 · Cited by 24
Okubo, M., Toromanović, A., Ebara, T., & Murase, T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.022 · Cited by 22
Streicher, R., Geisel, J., Weisshaar, C., Avci, H., Oette, K., Müller‐Wieland, D., & Krone, W. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37463-0 · Cited by 21
Familial chylomicronemia syndrome related chronic pancreatitis: a single-center study
Şışman, G., Erzin, Y. Z., Hatemı, İ., Çağlar, E., Boğa, S., Singh, V. K., & Şentürk, H. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60033-3 · Cited by 20
GPIHBP1 and the processing of triglyceride-rich lipoproteins
Beigneux, A. P. (2010) · Clinical Lipidology · doi:10.2217/clp.10.43 · Cited by 17
A novel APOA5 splicing mutation IVS2+1g>a in a Japanese chylomicronemia patient
Okubo, M., Ishihara, M., Iwasaki, T., Ebara, T., Aoyama, Y., Murase, T., & Hattori, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.046 · Cited by 15
Plasmapheresis in the Management of Severe Hypertriglyceridemia
Seda, G., Meyer, J. M., Amundson, D. E., & Daheshia, M. (2013) · Critical Care Nurse · doi:10.4037/ccn2013346 · Cited by 14
Missense mutation W86R in exon 3 of the lipoprotein lipase gene in a boy with chylomicronemia
Pašalić, D., Jurčić, Z., Stipančić, G., Ferenčak, G., Leren, T. P., Djurovic, S., & Stavljenić-Rukavina, A. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.01.029 · Cited by 13
AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice
Rip, J., van Dijk, K. W., Sierts, J. A., Kastelein, J. J. P., Twisk, J., & Kuivenhoven, J. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.08.008 · Cited by 11
Severe hypertriglyceridaemia. Treatment with plasmapheresis.
Izquierdo, M. J., & Abaigar-Luquin, P. (2012) · PubMed · doi:10.3265/nefrologia.pre2012.feb.11394 · Cited by 9
Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work
Marbach, J. A., McKeon, J. L., Ross, J. L., & Duffy, D. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1441 · Cited by 9
Foubert, L., Gennes, J. L. D., Benlian, P., Truffert, J., Li, M., & Hayden, M. R. (1998) · Human Mutation · doi:10.1002/humu.1380110148 · Cited by 6
Zimmer, M., Picarella, D., Liu, F., Bista, P., Lee, D. W., Vu, C. B., & Jirousek, M. R. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvb.34.suppl_1.6 · Cited by 5
[Successful treatment of severe hypertriglyceridemia with plasmapheresis--case report].
Hen, K., Bogdański, P., & Pupek‐Musialik, D. (2009) · PubMed · Cited by 5
[Vacuum sign of cerebrospinal fluid flow].
Manzella, D. J., Scalise, D. H., & Melero, M. J. (2014) · PubMed · Cited by 1
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Self-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 529
Self-citation
Metadata
- Authors
- Brahm, A. J., & Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Hegele, Robert A.
- ORCID
- Hegele, Robert A.
- Venue
- Nature Reviews Endocrinology
- Published
- 2015-03-03
- Volume
- 11
- Issue
- 6
- Pages
- 352-362
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W2067802636
- Cited by
- 356
- References
- 134
- Citations by year
- 2026: 32 · 2025: 26 · 2024: 37 · 2023: 28 · 2022: 35 · 2021: 33 · 2020: 43 · 2019: 30 · 2018: 36 · 2017: 25 · 2016: 20 · 2015: 9
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- lipoprotein lipase deficiency, apolipoprotein C-II, apolipoprotein A-V, genetic basis, pancreatitis risk, cardiovascular risk, dietary fat restriction, apolipoprotein C-III, ANGPTL3, new drugs
- MeSH terms
- Hypolipidemic Agents, Benzimidazoles, Diet Therapy, Humans, Hyperlipoproteinemia Type V, Hyperlipoproteinemia Type I, Niacin, Plasma Exchange, Plasmapheresis, Genetic Therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
